Breast Cancer Clinical Trial

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

Summary

A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Analytic Database to compare effectiveness (i.e., overall survival) of first line palbociclib + aromatase inhibitor (AI) versus AI alone treatment in postmenopausal women or men with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States clinical practices

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Confirmed HR+/HER2- status after MBC diagnosis.
Received palbociclib + AI or AI as first-line therapy

Exclusion Criteria:

Evidence of prior treatment with other CDK4/6I, AI, tamoxifen, raloxifene, toremifene, or Fulvestrant for MBC
First structured activity greater than 90 days after MBC diagnostic date
Treatment with a CDK4/6 inhibitor as part of a clinical trial

Study is for people with:

Breast Cancer

Estimated Enrollment:

2888

Study ID:

NCT05361655

Recruitment Status:

Completed

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

10017
New York New York, 10017, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

2888

Study ID:

NCT05361655

Recruitment Status:

Completed

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.